ValiRx PLC, a life science company focused on early-stage cancer therapeutics and women's health, has appointed a project manager to lead the preclinical development of its in-licensed triple negative breast cancer treatment, CLX001.
News
Read the latest People Pathways newsletter for your monthly round up of employee engagement activities.
PRESS RELEASE
PrecisionLife Enters into a Multi Target R&D Collaboration Agreement with Ono Pharmaceutical
- Scott Maidment appointed as Head of HTS to lead the new service
- Expanded facilities gives Company total of 20,160 sq. ft at Granta Park, Cambridge, UK
Research targeted at identifying novel inhibitors or activators of Kv3.1 mutation
Have you noticed how the topic on everyone’s lips in the world of work has shifted from ‘how do we make hybrid working work?’ to ‘how do we engage and retain our staff?’
AMSBIO offers a wide range of small molecules to provide scientists with targeted tools to direct cell fates, making them crucial in areas including regenerative medicine and cancer research.
Small molecules are cell-permeable organic compounds with low molecular weights, which are chemically produced, in contrast to larger molecules such as proteins which are often produced via biological means. Small molecules are crucial components of an affordable cell culture toolkit that can be used to maintain, reprogram, and differentiate cells.
- Capivasertib alongside hormone therapy doubles time before advanced breast cancer progresses
- Combination set to become new treatment option for patients with advanced forms of most common type of breast cancer
- Inhibitor of cancer-driving protein AKT shows broad benefits in patients with ER positive, HER2 negative breast cancer
A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major phase III clinical trial.
Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant GPCR targets for structure-based drug design
Aptamer Group plc, the developer of novel Optimer® binders to enable innovation in the life sciences industry, announces a selection of new contract wins where Optimer technology is being explored by partners to offer new strategies for therapeutics and potentially offer improved assay sensitivity and selectivity over antibodies.